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Abstract
The innate immune system is the primary line of defense to protect the host from
pathogen infection. Mammalian cells produce inflammatory cytokines and
chemokines in response to innate immune signals and their expression is tightly
regulated. IFN-gamma Inducible Protein (IP-10), also known as C-X-C motif
chemokine 10 (CXCL10), is an inflammatory chemokine belonging to the CXC
chemokine family. CXCL10 is chemotactic for many inflammatory cells, including
macrophages, and altered expression of CXCL10 is associated with
inflammatory diseases, including lupus nephritis and other autoimmune diseases.
The Fli-1 transcription factor is a member of the Ets gene family and regulates
the immune response, along with other cellular processes including its role in the
pathogenesis of renal injury and systemic lupus erythematosus (SLE). Previous
data has shown that Fli-1 heterozygous NZM2410 mice, a murine model of lupus
with decreased Fli-1, had significantly decreased infiltration of inflammatory cells
including macrophages in kidney. Similarly, in MRL/lpr lupus mice with
decreased Fli-1, Decreased T cell infiltrates and CXCL10 levels in the kidney
was founded. We hypothesize that Fli-1 is a critical regulator in directly
modulating the expression of CXCL10. In this study, Fli-1 protein expression in
endothelial cells transfected with Fli-1 specific siRNA was significantly decreased
compared to the expression of Fli-1 in cells transfected with control siRNA.
Additionally, endothelial cells transfected with Fli-1 specific siRNA produced
significantly lower amounts of CXCL10 compared to cells transfected with control
siRNA after stimulation by Toll-like receptor (TLR) 4 ligand, lipopolysaccharide
4

(LPS). Chromatin immunoprecipitation (ChIP) assay was performed to show that
Fli-1 binds Ets binding sites (GGAA/T) within the mouse CXCL10 promoter. The
human CXCL10 gene promoter was used to perform a transient transfection to
determine that Fli-1 actively promotes transcription from the CXCL10 promoter.
Mutation of the DNA binding domain of Fli-1 demonstrated that Fli-1 activates
transcription of CXCL10 in both indirectly and directly ways, likely with the
assistance of co-factors or post-transcriptional modifications. Together, the
results indicate that Fli-1 is a novel, critical transcription factor in regulating the
expression of the pro-inflammatory chemokine CXCL10 and provides a possible
mechanism for the protective effect of decreased Fli-1 expression in lupus and
other inflammatory autoimmune diseases.
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Chapter 1 - Introduction
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is
involved in inflammation in many different organs of the body, including the
kidney, joints, skin, and brain causing symptoms that range from rashes, arthritis,
heart disease vasculitis, serositis, and nephritis [1-3]. Approximately 90% of SLE
patients are women aged 20-40 years and the occurrence of lupus is high in
young African American women [1, 3]. The recent peak in mortality of SLE
patients over the past 30 years has brought major concerns about the
development of the disease and implementing new therapies to treat it. Among
SLE patients, 50-70% of the mortality is due to lupus nephritis [1]. Lupus
nephritis is a type of glomerulonephritis that is commonly seen in SLE patients. It
is frequently associated with tubulointerstitial and/or vascular lesions in
combination with impaired renal function, edema, proteinuria and hypertension
[1]. The pathogenesis of lupus nephritis is poorly understood and much of what
we know of the disease comes from animal models that exhibit lupus-like
symptoms, including glomerulonephritis. Glomerulonephritis is initiated through
renal deposition of immune complexes that consequently activates complement
and Fc receptors [1]. In the late 1960’s, researchers discovered that patients
with lupus nephritis contain autoantibodies against double stranded DNA [1].
With these antibodies acting against self, the kidney initiates the release of
inflammatory cytokines and chemokines attracting inflammatory cells including
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macrophages, dendritic cells, T cells and B cells into the glomerular and
tubulointerstitial areas of the kidneys [4]. The infiltration of inflammatory cells,
such as T helper type 1 (Th1) cells, initiates a cascade of events that contributes
to the progressive deterioration of kidney structure and function.
Taking a closer look at the inflammatory cell types that infiltrate the kidney
in lupus nephritis patients, T lymphocytes and B lymphocytes initiate the
accumulation and infiltration of these cell types within the kidney [5]. T
lymphocytes are composed of two classes, CD4 and CD8 cells, identified by their
distinct surface markers. CD8 cells are cytotoxic T cells [5]; therefore they kill
foreign pathogens on site, however CD4 T cells differentiate into effector
subsets, the dominant ones being Th1 and Th2 cells [5]. Interleukin-12 (IL-12)
drives the differentiation of naïve CD4 T cells to their Th1 cell subset [5]. Th1
cells release chemokines, such as IFN-γ, to activate macrophages and recruit
inflammatory mediators. Activation of monocytes causes them to mature into
macrophages. Macrophages are antigen-presenting cells that induce
phagocytosis of bacterial pathogens [5]. In addition to expressing IFN-γ, Th1
cells can express TNF-α and TNF-β, which facilitate expression of adhesion
molecules in blood vessels [6]. The release of these chemokines may cause
local tissue damage. Th1 cells also release granulocyte macrophage colonystimulating factor (GM-CSF) that stimulates bone marrow stem cells to produce
monocytes [5]. The release of IL-4 by CD4 lymphocytes leads to Th2 cell
differentiation and, in turn, Th2 cells release a number of effector molecules
including IL-4, IL-5, IL-6, IL-10, and IL-13 [7]. These chemokines target
7

extracellular parasites and play a role in asthma and allergies. Overall, Th1 cells
initiate cell-mediated immunity and inflammation, while Th2 CD4 T lymphocytes
regulate antibody-mediated immunity [5].
Dendritic cells (DCs) are equally involved in inflammation as
macrophages, B-lymphocytes, and CD4 and CD8 cells and their subsets. DCs
are derived from committed DC progenitors within the bone marrow and migrate
to lymphoid and non-lymphoid tissue [8]. Between the two classes of DCs,
conventional (cDC) and plasmacytoid (pDC), cDCs are antigen presenting and
activate naïve T cells, and pDCs respond to viral and bacterial infections by
producing large amounts of IFN-α and IFN-β [5].
The pathogenesis of lupus nephritis is not fully understood. As mentioned
previously, due to autoantibody production, complement and Fcγ receptors
(FcγR) are activated and initiates the formation of immune complexes [1]. The
activation of complement leads to glomerular injury which essentially leads to
glomerulonephritis, similarly with FcγRs [1]. There are a number of nuclear
antigens and autoantibodies implicated in the pathogenesis of lupus nephritis
including: dsDNA, ssDNA, chromatin, histone, SSA, SSB, ribonucleoprotein and
anti-C1q antibodies [1]. All of which have been found in the kidneys of LN
patients. How these anti-dsDNA and autoantibodies are deposited in the kidneys
are not fully elucidated. There are a number of theories; however none have
been proven or have any evidentiary support [1]. However, current studies are
looking into possible ways to regulate inflammation within this progressive
disease.
8

Like many inflammatory diseases, cytokines and chemokines are closely
involved in lupus nephritis development [1]. Inflammatory cells are all recruited by
inflammatory cytokines, and all of these cell types contain a common chemokine
receptor, CXCR3. CXCR3 is a receptor for C-X-C motif chemokine 10 (CXCL10)
the inflammatory chemokine this study is focused on. Detailed discussion
regarding CXCL10 will be presented in another section.

The Friend Leukemia Insertion Site 1 Transcription Factor
The Ets gene family is composed of a number of transcription factors with
a winged helix-turn-helix structure essential for protein-protein interaction and
DNA binding [9]. Ets transcription factors are involved in various cellular
processes, including the immune response, cellular proliferation, development,
differentiation, transformation, and apoptosis [10]. All members of the Ets gene
family contain an approximately 85 amino acid domain that binds to the
conserved DNA binding motif (GGAA) [10]. One family member, the protooncogene Friend Leukemia Insertion site 1 (Fli-1) transcription factor, regulates
the immune response along with other cellular processes such as cell growth,
proliferation, maturation, and survival [9]. Fli-1 recognizes the consensus DNA
binding motif GGAA/T and, upon binding, can be either a positive or negative
regulator of transcription [9].
Several studies have implicated the Fli-1 transcription factor in SLE and
lupus nephritis disease pathogenesis. The overexpression of the Fli-1 gene in
transgenic mice has been shown to increase infiltration of B and T lymphocytes
9

within the kidneys, eventually leading to death due to tubulointerstitial nephritis
and glomerulonephritis [11]. Because complete targeted disruption of the Fli-1
gene has resulted in embryonic death within the animal models, researchers
decided to investigate the reduced expression of Fli-1 on disease development in
lupus disease [12]. MRL/lpr mice and NZM2410 mice are widely used murine
models of lupus [13]. Fli-1 heterozygous (Fli-1+/-) congenic MRL/lpr mice with
reduced expression of Fli-1 as well as Fli-1+/- congenic NZM2410 mice were
generated by backcrossing with B6 Fli-1+/-mice. [11, 14]. As disease progressed,
Fli-1+/-MRL/lpr mice and Fli-1+/- NZM2410 mice had significantly decreased serum
levels of total IgG and anti-dsDNA antibodies compared to the Fli-1+/+ littermates
[11]. Both in vivo and in vitro production of Monocyte Chemoattractant Protein-1
(MCP-1) chemokine was significantly decreased in Fli-1+/- MRL/lpr mice and MS1
cells where Fli-1 is knocked-down. Also, the Fli-1+/- MRL/lpr mice and Fli-1+/NZM2410 mice had markedly decreased proteinuria and pathologic renal scores.
At 48 weeks of age, 100% of Fli-1+/- MRL/lpr mice were alive, in contrast to only
27% of homozygous (Fli-1+/+ mice) littermates [11]. Notably, Fli-1+/- NZM2410
mice with reduced expression of Fli-1 transcription factor had a marked reduction
in nephritis, necrosis, and proteinuria compared to wild-type NZM2410 mice [14].
This is the same with the Fli-1+/- MRL/lpr mice. Since infiltration of inflammatory
cells into kidneys plays an important role in glomerulonephritis development, the
inflammatory cells were quantitated and compared from Fli-1+/-NZM2410 mice
and wild-type littermates. In previous studies conducted in our lab, Fli-1+/NZM2410 mice and wild-type littermate controls were sacrificed, the kidneys
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were removed, and inflammatory cell infiltration analyzed. In previous studies
we’ve seen a statistically significant decrease in all inflammatory cells including
CD3+ T cells, CD19+ B cells, Ly-6B.2+ monocytes/macrophages and CD11b+
dendritic cells in the kidneys from Fli-1+/-NZM2410 mice compared to wild-type
controls. Ly-6B.2+ cells decreased 44%, and all other inflammatory cells
decreased more than 50% in the kidneys from Fli-1+/- NZM2410 mice, as
compared to wild-type controls. Notably, there was a 70% decrease in CD19+
cells in Fli-1+/-NZM2410 mice versus wild-type controls [11].
Because chemokines are known to play an important role in inflammatory
cell infiltration, the expression of inflammatory cytokines and chemokines in
kidneys from wild type and Fli-1+/-NZM2410 mice was also studied. The
investigators observed significantly lower expressions of CCL5, MCP-1 and IL-6
in kidneys from Fli-1+/-NZM2410 mice versus the kidneys of wild-type controls
[14-16]. Both in vivo and in vitro production of MCP-1 was significantly
decreased in Fli-1+/-MRL/lpr mice and Fli-1 knockdown MS1 cells and in the
kidney. Furthermore, our lab has demonstrated that Fli-1 directly regulates
expression of inflammatory cytokines including MCP-1, Regulated upon
Activation, Normal T Expressed and Secreted (RANTES), and IL-6, all of which
are associated with lupus nephritis [11, 14, 16-19].

Inflammatory signaling in innate immunity and Inflammation:
Innate immunity is an important part of the immune system in an
organism, which defends itself from invading pathogens in a non-specific manner
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[20]. The Toll-like receptor (TLR) was initially discovered in Drosophila, and later
it was discovered that Drosophila [20]. The first human TLR was reported in
1997, and now there are 10 functional Toll-like receptors in humans and 12 in
mice [21]. TLRs are pattern recognition receptors (PRRs) that recognize
pathogen associated molecular patterns (PAMPs) found on proteins, lipids,
nucleic acids and lipoproteins, which are expressed on virus, bacteria, fungi and
parasites [22]. Toll-like receptors have been identified in immune cells such as
monocytes, dendritic cells, B cells and non-immune cells such as epithelial cells
[22]. TLRs consist of an extracellular like receptor region, a transmembrane
domain and a cytoplasmic Toll/IL-1 receptor domain [21]. Upon binding and
activation by ligands, TLRs recruit a set of adaptor proteins such as Myeloid
differentiation primary response protein 88 (MyD88) and TRIF-related adaptor
molecule (TRAM), and then activate downstream kinases and transcription
factors including Nuclear Factor-Kappa B (NF-kB), activator protein 1 (AP-1),
Interferon regulatory factor 3 (IRF3) or IRF7 that regulate the expression of
inflammatory cytokines and chemokines [23]. For example, the TLR-4 cascade
can be MyD88 dependent, which in turn may lead to the stimulation of
inflammatory cytokines, or MyD88 independent, which results in the expression
of interferon inducible genes [24]. The Ets family is known to regulate
inflammatory cytokine expression through TLR-4 [16, 25].
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Chemokine (C-X-C motif) ligand 10 and CXCR3 receptor
Chemokines are a subfamily of cytokine-like molecules that induce chemotaxis
and regulate functional properties of various leukocytes during inflammation [26].
The four groups of chemokines are distinguished by number and by the spacing
of two conserved cysteine residues on the N-terminus (as shown in Figure 1).
Two N-terminal cysteine residues, separated by a single variable amino acid,
determine the CXC subgroup [27].The CXC subgroup is further divided into two
subdivisions. The ERL positive motif, containing glutamine, arginine, and leucine
near the N-terminal, and the ERL negative motif, which do not contain glutamine,
arginine, and leucine near the N-terminal CXCL9, CXCL10, and CXCL11, are
part of the ERL negative motif [26, 27]. All three CXC chemokines have a similar
structure and share a ligand receptor, CXCR3 [28]. A G-protein coupled
receptor, CXCR3 is expressed on many immunological cell types, such as
activated T-cells, specifically Th1 CD4+ cells, as well as natural killer cells (NK)
and CD8+ T cells. Increased recruitment of each of those cells to the site of
infection can lead to chronic inflammation [4, 29-31]. The CXCR3 receptor is also
expressed on myeloid dendritic cells, leukemic B-cells, and endothelial cells
amongst other cell types [4].
As mentioned previously, chemokine (C-X-C motif) ligand 10 (CXCL10) is
an interferon gamma inducible protein and may be referred to as IP-10 [32]. The
human CXCL10 gene was initially found and identified as an early response
gene in a monocyte-like cell line, U937 cells [26, 33]. The CXCL10 gene is
located on chromosome 4, band q21. It has an open reading frame of 1173 bp,
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which encodes a 98 amino acid protein and contains 4 exons, and a molecular
mass of 10kDa, hence the name CXCL10 [26, 33]. The gene has been shown to
regulate chemotactic and mitogenic activities associated with inflammation and
cell proliferation. The human CXCL10 amino acid sequence has 63% homology
with murine CXCL10 cDNA [33].
CXCL10 is expressed in a variety of cell types including monocytes,
fibroblasts, neutrophils, keratinocytes, astrocytes, mesangial cells, and
endothelial cells [26]. Functional characteristics of CXCL10 include its pleiotropic
capabilities of inducing apoptosis, cell growth, and proliferation, as well as its role
in inflammatory and infectious diseases and tumor growth. CXCL10 is a
chemoattractant protein for monocytes, Th1 cells, DCs, and NK cells [4, 33, 34].
The expression of CXCL10 drives the recruitment of immune competent cells
and the formation of lymphocyte infiltrates in autoimmune inflammation [26]. Th1
cells, for example, are highly recruited by CXCL10 chemokine due to the high
amount of IFN-γ that is being secreted by Th1 cells themselves. IFN-γ promotes
the secretion of CXCL10 in various cell types, including Th1 cells. This, in turn,
causes CXCL10 to recruit more Th1 cells, thus displaying a positive feedback
loop [26, 35]. The recurring positive feedback loop leads to both the innate and
adaptive immune response and, unfortunately, to the high inflammation that
cause tissue damage [33].
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CXCL10 and Diseases
The manifestations of autoimmune diseases stem from effector
mechanisms of the immune system that become directed towards self [5]. Given
the role CXCL10 plays in the recruitment of inflammatory cells and the immune
response, it is not surprising that the gene is implicated in the pathogenesis of
various diseases. Studies have shown that CXCL10 is expressed in many Th1type inflammatory diseases including type 1 diabetes, psoriasis, multiple
sclerosis, atherosclerosis, rheumatoid arthritis (RA), transplant rejection, and
systemic lupus erythematosus (SLE) [26]. As mentioned previously, SLE is
characterized by activation of T and B lymphocytes, autoantibody production,
and the development of immune complexes resulting in damage to the tissue and
organs [26]. Development of many autoimmune diseases can be contributed to
abnormal T helper cell cytokine production, notably, CXCL10, which is especially
relevant to SLE and the current study. CD4+/CD8+ T cells that infiltrate the
kidney express the CXCR3 receptor, which upon activation causes the
production of CXCL10 [28-30]. When overproduced, CXCL10 leads to the
recruitment of more Th1 inflammatory cells causing damage to the organs [34].
Evidence linking CXCL10 and SLE has been provided in many recent studies
[26]. In one study, researchers saw increased serum levels of CXCL10 in SLE
patients [36]. After measuring CXCL10 levels and disease activity in SLE and RA
patients they also measured MCP-1 levels as well, since MCP-1 is a known
inflammatory chemokine and an early marker for other inflammatory diseases.
MCP-1 elevation was detected in high levels of disease activity in both groups,
15

RA and SLE. However, researchers concluded that the elevated levels of MCP-1
were generated from increased inflammation and were not necessarily
dependent upon disease activity [36]. Alternately, the investigators concluded
that CXCL10 serum levels increased in relation to severe disease activity after
measuring anti-DNA antibodies [36]. Those findings suggest that CXCL10 is an
indicator of SLE activity [36]. In recent plasma chemokine studies, researchers
observed increased levels of CXCL10 produced by peripheral blood
mononuclear cells (PBMC) from SLE patients [37]. The objective was to
determine whether there was chemotactic preference for Th1 chemokines or Th2
chemokines or both in SLE patients. Elevated levels of CXCL10, detected from
the PBMCs, were significantly higher in SLE patients versus healthy patients
[37]. Other evidence linking CXCL10 and SLE are the increased levels of
CXCL10 seen in the cerebrospinal fluid of SLE patients. The exact role of
CXCL10 within the pathogenesis of SLE has yet to be identified [38]. Previous
reports demonstrated that NF-kB (nuclear factor kappa-light-chain-enhancer of
activated B cells) transcription factor is involved in regulating expression of
CXCL10 [39].

Fli-1, SLE, and CXCL10
CXCL10 is a major macrophage and T-cell chemotactic cytokine, and our
lab observed significantly reduced macrophage and T-cell infiltration into the
kidney from Fli-1+/- NZM2410 mice with reduced expression of Fli-1 compared to
that from wild-type controls [16]. Furthermore, another study found that the
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kidney CXCL10 concentrations from Fli-1+/- MRL/lpr mice were significantly lower
compared to these from wild-type MRL/lpr controls [28]. There were significantly
fewer T cells in the kidney, significantly reduced T cells expressing CXCR3, and
decreased CXCR3 expression in the kidneys, all of which supports Fli-1’s role in
regulating CXCL10-CXCR3 recruitment of T cells to the kidney. Taking all
information into account, this suggests that Fli-1 transcriptionally controls the
expression of CXCL10. In addition, we have preliminary data demonstrating that
endothelial cells transfected with specific Fli-1 siRNA had markedly reduced
expression of Fli-1 protein and produced significantly decreased amounts of
CXCL10 after stimulation with TLR4 ligand, lipopolysaccharide (LPS), compared
with endothelial cells transfected with control siRNA. Analyzing the promoter
region of CXCL10 revealed there are many potential Ets DNA-binding sites in the
CXCL10 promoter. This leads us to our hypothesis that Fli-1 is a critical
regulator in directly modulating the expression of CXCL10, which is
associated with inflammation in autoimmune diseases and other
inflammatory disease development. The below study was designed to test this
hypothesis by determining if Fli-1 regulates the expression of CXCL10 and
identifying the mechanism behind this regulation.
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Chapter 2 – Hypothesis

Fli-1 is a critical regulator in directly modulating the expression of CXCL10,
which is associated with inflammation in autoimmune diseases and other
inflammatory disease development.

Specific Aims
Specific Aim 1: To confirm that Fli-1 regulates the expression of CXCL10.
Specific Aim 2: To investigate the mechanism(s) of how Fli-1 regulates
the expression of CXCL10.
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Chapter 3 – Materials and Methods

Cells
Endothelial cells (EC) are a cell type of choice for multiple reasons. As
mentioned previously ECs contain the CXCR3 receptor and it also expresses
CXCL10 [4]. Previous studies have demonstrated that Fli-1 is highly expressed
in ECs [40]. MS1 cells, a murine pancreatic islet endothelial cell line, were
purchased from the American Type Culture Collection (ATCC, Manassas, VA)
and maintained with DMEM containing 5% fetal bovine serum (FBS). Human
Umbilical Vein Endothelial cells (HUVECs) were purchased from Lonza (Basal,
Switzerland) and maintained in EBM-2 Basal Medium supplemented with EGM-2
SingleQuot Kit growth factors. NIH3T3 cells were purchased from ATCC and
maintained with DMEM with 10% fetal bovine serum and 1%
penicillin/streptomycin. All cells were grown at 37°C in 5% CO2.

siRNA Transfections
MS1 cells and HUVECs were cultured to confluence in sterile T-75 Falcon culture
flask with complete growth media. To remove cells from the flasks, they were
treated with 0.05% Trypsin (MS1) or TrypLE (HUVECs) and incubated at room
temperature for 1-2 minutes until cells came off the plate. Both MS1 cells and
HUVECs were neutralized with growth media and counted using a
hemocytometer. Once plated in a 6-well plate at 0.5 x 105 cells/well with each
well containing 2 ml of media, the cells were incubated at 37C, 5% CO2 for 24
19

hours in preparation for transfection. After the 24hr incubation, the media was
removed from the cells, replaced with fresh media, and placed back into the
incubator for one hour to equilibrate. An RNAi duplex was prepared by combining
5nmol Stealth Silencer Human Fli-1 siRNA (Ambion, Walthan, MA) oligo with
Opti-MEM medium (Thermo Fisher Scientific, Waltham, MA) for Fli-1 transfection
and siRNA Negative Control, Med GC (Thermo Fisher Scientific) and Opti-MEM
medium for the control. An RNAi Max solution was prepared containing 25pmol
of lipofectamine as the transfection reagent and combined with Opti-MEM
medium. Two solutions of RNAi Max were prepared for the Fli-1 transfection and
the control, respectively. The RNAi Max and the RNAi duplex were combined,
equal amounts of the mixture were added to the control only 6-well plate and the
Fli-1 only 6-well plate. The plates incubated overnight.

Lipopolysaccharide (LPS) Stimulation
LPS was used to activate the TLR signaling pathway in cells to observe CXCL10
production. The cells were cultured in a T-75 flask to 80% confluence and plated
onto a 6-well plate at a concentration of 1 x 105 cells/well, each well containing 2
ml of media and incubated at 37C, 5% CO2 for 24hrs. The media was changed
the next day. Cells were stimulated with TLR4 ligand, lipopolysaccharide (LPS)
to induce CXCL10 production. Cells were stimulated with 1g/mL of LPS, and
samples were collected at the 0, 2, 6 and 24-hour time points. A dosage
response assay was performed to ensure the appropriate amount of LPS was
20

being administered to the cells. We stimulated the cells with 0.25g/ml, 0.5g/ml,
1g/ml, 5g/ml, and 10g/ml of LPS. The supernatants were collected at 2 hours,
6 hours and 24 hours after stimulation and stored at -80C.

Immunoblot Analysis
Immunoblots were performed to monitor the efficiency of siRNA knockdown.
Cells were collected in 1X Phosphate Buffer Saline (PBS) and lysed with
Radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5; 150 mM
NaCl; 1% Triton X-100; 0.5 % deoxycholate; 0.1 mM EGTA; 1.0 mM EDTA; 0.1%
SDS and protease inhibitor mixture). Equal amounts of each sample were loaded
and ran on a 12% Tris Glycine SDS-PAGE gel (Novex, Life Technologies) under
reducing conditions. The proteins were transferred onto a polyvinylidene
difluoride membrane and blocked for 1 hour in Odyssey Blocking Buffer (LI-COR,
Lincoln, Nebraska). The membrane was later probed with 1:100 dilution of
specific rabbit polyclonal Ab against Fli-1 and 1:200 dilution of β-actin Rabbit
mAb (Cell Signaling Technology). After three washes with PBS containing 0.1%
Tween 20 (PBST), the membrane was incubated with donkey anti-rabbit IgG
secondary antibody (LI-COR)). Chemiluminescence signals were captured using
an Odyssey chemilminescence and infrared imager (LI-COR). The expression
levels were quantified by Ascent densitometry software.
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Enzyme-linked Immunosorbent Assay
A 96-well polystyrene microplate was coated with antihuman CXCL10 capture
antibody and incubated overnight at room temperature. After 2-3 washes, the
plate was blocked with reagent diluent (1% bovine serum albumin in PBS), and
samples were added after a second wash. Recombinant human CXCL10
standards were added following a seven point standard curve starting at
2000pg/ml with a 2-fold serial dilution. Standards and samples were sealed and
incubated at 4C overnight. Plates were aspirated, washed, and separately
probed with biotinylated goat anti-human CXCL10 detection antibody,
streptavidin-HRP, and finally, color substrate solutions, H2O2 and
Tetramethylbenzidine. Washes were conducted between each step. To stop the
reaction, the plate was coated with an acid solution, 2N H2SO4. CXL10 levels
were measured using a microplate reader at a wavelength of 450nm.

IP-10/CXCL10 Primers for ChIP Assay
To design the primers for CXCL10, we obtained the 5’ UTR from the murine
CXCL10 sequence using the Ensembl genome database (www.ensembl.com,
gene number ENSMUSG00000034855) and identified the promoter region. Next,
the sequence was uploaded into the Genomatix MatInspector program to identify
potential ETS transcription factor binding sites within the promoter region of
CXCL10.

Once those sites were identified through the MatInspector program,

we further confirmed our findings by using the Clustal X 2.1 program to visualize
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the sequence. With this information, we proceeded to design appropriate primers
for the promoter region of CXCL10. According to Thermofisher Scientific, the
most ideal primers should be low in GC count, with an appropriate length of 15 –
20 nucleotides, melting temperatures around 60C, and similar TM’s for each
primer pair along with other stipulations. An oligonucleotide calculator
(http://biotools.nubic.northwestern.edu/OligoCalc.html) was used to ensure these
requirements were met. The primers are listed in Table 2.

ChIP Assay

A Chromatin Immunoprecipitation (ChIP) Assay was performed to determine if
Fli-1 directly binds to the promoter region of CXCL10 using the EpiTect ChIP
OneDay kit from QIAGEN. Approximately 2-4 million cells were cultured in
preparation for the ChIP Assay. Cells were fixed with fresh fixing buffer (1%
Formaldehyde in 1X PBS) and washed with 1X PBS before harvesting with cell
harvesting buffer containing protease inhibitor cocktail (PIC) in 1X PBS. Cells
were then lysed and sonicated to obtain ChIP-ready chromatin. ChIP chromatin
was isolated via immunoprecipitation where the anti-Fli-1 rabbit polyclonal
antibody was used. A normal rabbit IgG antibody was used for a negative control
and the complete IP Fraction as the positive control. DNA elution buffer and
ChIP-Grade Proteinase K were added to the ChIP chromatin IP fraction to isolate
the targeted DNA fraction. DNA purification was performed through a series of
washes and elution buffer to create a viable ChIP fraction DNA sample.
23

Real Time qPCR
Real Time qPCR was used to quantitate our ChIP assay results and was
performed in triplicate. We used our ChIP fraction DNA samples and the primers
that were designed for the CXCL10 promoter. The experiment was performed
following the basic steps of denaturation, annealing, and extension. Primers,
DNA, Water, and Bio-Rad SybrGreen Supermix (contains polymerase, dNTPs,
MgCl2, and dyes) was combined and loaded onto the PCR plate and amplified
using a thermocycler. For the control, we used MCP-1 primer. These controls
have been published in previous papers by our lab [15, 16, 25]. Once the primers
detect the promoter region following IP with anti-Fli-1 antibodies, the RT-pCR
machine puts out critical threshold values. Our data is quantitated based on
these critical threshold (CT) measurements.. CT values are defined as changes in
fluorescence per PCR cycle number at the set base threshold. To normalize our
input, specific antibody was compared to the % input value for each
immunoprecipitation represented as CT (% Input CT – (specific antibody CT –
Dilution Factor). Genomic DNA was calculated and represented as CT (% Input
CT – Fli-1 specific antibody CT). CT (genomic input) and CT (specific antibody)
are the mean threshold cycles of PCR performed. Fold Enrichment (2CT) was
determined based on the 2-fold change of CT. The error bar represents
standard deviations.
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Reporter & Expression Constructs
Primers were designed specifically for the promoter region of CXCL10, using the
previously mentioned technique. To clone the full length CXCL10 promoter
region, -2069bp upstream of the transcription start site, we used the ChIP 1
reverse primer (5' CAC TTG GGT TCA TGG TG 3') and ChIP 14 forward primer
(5' GAA TTC GGA GGT CTA CCT 3') that were designed previously for the ChIP
Assay. These two primers along with restriction enzymes Kpn1 and Sma1
(underlined) were used to obtain the entire 2069bp promoter region through
cloning. Genomic DNA isolated from a B6 mouse was amplified using
polymerase chain reaction (PCR). DNA concentration was measured after
isolation. Although were able to isolate and clone the murine CXCL10 promoter,
we were able to obtain the human CXCL10 promoter already sequenced and
inserted into the pGL4 vector. The CXCL10 human promoter was used for our
DNA transfections. It was obtained from Dr. David Proud (University of Calgary,
Alberta, Canada) and initially generated from human genomic DNA [41]. The
972bp promoter construct corresponds to the human CXCL10 gene and its
promoter sequence ranges from -875 to +97 in relation to the transcription start
site [41]. In comparing, both, the murine and human CXCL10 promoter
construct, we found 63% homology within the two sequences. This percentage
was calculated based on neighbor joining tree method using ClustalX2.1
program. Taking this information in account, we opted to use the human CXCL10
promoter construct for the DNA transfections.
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The following expression constructs were used in the transient
transfection assays. The murine Fli-1 expression construct, containing a 5’ kozak
sequence and a flag tag, was provided to our laboratory by Dr. Dennis Watson
(Medical University of South Carolina) [42]. The Fli-1 expression construct was
cloned in the pCDNA3.0 vector (Life Technologies), which is under regulation of
the CMV (Human cytomegalovirus) promoter. DNA transfections were also

performed using the human Fli-1 gene cloned into the pSG5 expression
vector (AgilentTechnologies, Santa Clara, CA) and a Fli-1 DNA-binding
mutant construct inserted into the pSG5 vector. This mutation contains a
single amino acid change of tryptophan 321 to arginine preventing DNA
binding, which was provided to our laboratory by Dr. Maria Trojanowska
(Boston University School of Medicine Arthritis Center, Boston, MA) [42].

DNA Transfections
The NIH3T3 cell line, also known as murine embryonic fibroblast cells, contain no
endogenous Fli-1 and are a commonly used cell line for DNA transfection.
NIH3T3 cells were seeded in a 6 well plate at a concentration of 4x105 cells/well
and incubated at 37C, 5% CO2 overnight in preparation for the transfection.
Cells were transfected using Fugene 6 (Promega) as the transfection reagent
and 0.1g of the pGL4/human CXCL10 reporter construct. The Fli-1 expression
vector was transfected into the cells in increasing doses (0.025g, 0.05g, 0.1g,
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0.2g, 0.25g, 0.5g and 1g) and empty expression constructs (pcDNA or
pSG5) was also added so that equal amounts of total DNA were transfected into
the cells. A Renilla luciferase construct (pRL/TK) was also transfected into the
cells to normalize for transfection efficiency. After transfection, the cells were
incubated at 37C, 5% CO2 for 48 hours. To harvest the cells, they were washed
with sterile 1X phosphate buffer saline and then collected in passive lysis buffer
in preparation for the next experiment, the luciferase assay.

Luciferase Assay
Using the Dual-Luciferase Reporter Assay System (Promega) and the
Luminoskan Ascent Microplate Luminometer (Thermo Fisher Scientific, Waltham,
MA), we measured luciferase activity within our NIH3T3 cells. Briefly, 20μl of the
cell lysate was placed into white walled wells of a 96-well plate. Using the
luminometer, one hundred microliters of the provided Luciferase Assay Reagent
II was added to the lysate, a brief waiting period observed and then the luciferase
value recorded. Next, 100 μl of Stop and Glo Reagent was added to the samples,
a brief waiting period observed and the Renilla luciferase value recorded. We
normalized transcription activity to our Renilla luciferase construct pRL/TK
(Promega), which was co-transfected into our cells. Fold activation was
calculated by dividing normalized luciferase activity over pGL3 basic and
presented as mean + standard error.
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Statistics
To determine significance within the data, an unpaired, two-tailed Student’s t-test
based on equal or unequal variances was conducted between two groups in the
DNA transfection experiments. P values less than 0.05 or 0.01 were determined
as statistically significant. Significant differences in CXCL10 production were
determined via analysis of standard curve with Prism software from GraphPad
(San Diego, CA) and two-tailed Student t-test (Microsoft Excel), which were
calculated based on variance.
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Chapter 4 – Results

Specific Aim 1- To confirm that Fli-1 regulates the expression of CXCL10
Inhibiting expression of Fli-1 leads to significantly decreased production of
CXCL10
CXCL10 is a chemoattractant for inflammatory cells and reduced expression of
Fli-1 resulted in decreased inflammatory cell infiltration in kidneys in murine
model of lupus (see Table 1) [19]. We have found that endothelial cells in
glomeruli express high amounts of Fli-1 protein [40]. Given that CXCL10
expression was decreased in Fli-1(+/-) MRL/lpr mice [28], we first chose to
determine if inhibiting expression of Fli-1 affects production of CXCL10 in
endothelial cells. Both the murine endothelial cell line, MS1, and primary human
endothelial cells, HUVECs, were transfected with Fli-1 specific siRNA and
negative control siRNA, as described in the Methods section. The cells lysates
were collected with RIPA buffer and an immunoblot was performed to measure
the Fli-1 protein. As shown in Figure 2 and Figure 3, the expression of Fli-1
protein was inhibited after transfection with Fli-1 specific siRNA compared to the
cells transfected with control siRNA. To determine the appropriate concentration
of LPS to use on endothelial cells, a dosage response assay was performed on
untransfected cells. Figure 4 shows that increasing the dosage of LPS to murine
endothelial cells increases the amount of CXCL10 up until 1g/ml. At this point,
the amount of CXCL10 decreases. Based on these results we chose to treat the
cells in future experiments with 1g/ml LPS.
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To determine if the expression of Fli-1 affects production of CXCL10 in
endothelial cells, MS1 endothelial cells were transfected with Fli-1 specific siRNA
and control siRNA, and stimulated with 1 g/ml of LPS to induce an inflammatory
response. The supernatants were collected at 0, 6 and 24 hours after stimulation
and the concentration of the CXCL10 protein measured by ELISA. As shown in
Figure 5, the production of CXCL10 in MS1 cells transfected with specific Fli-1
siRNA was significantly reduced compared to the cells transfected with control
siRNA at 6 hours and 24 hours after stimulation (mean SD, 141.8  61.42 pg/ml
versus 146.19  80.28 pg/ml before stimulation – 0 hours,
and 645.7  167.1 pg/ml versus 336.2  93.26 pg/ml at 6 hours after LPS
stimulation, P value = 0.009967; and 1493.75  392.35 pg/ml versus 540.01
 187.37 pg/ml at 24 hours after LPS stimulation, P value = 0.004096) (P < 0.05
for each comparison; n = 2 (6 replicates per group). Decreased amounts of
CXCL10 in the cells transfected with specific Fli-1 represented more than a 50%
reduction compared to the cells transfected with negative control siRNA.
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Figure 2. Expression of Fli-1 was inhibited in murine endothelial cells with
specific Fli-1 siRNA transfection
Murine endothelial cells were treated with 20nmol Stealth silencer mouse Fli-1
siRNA or siRNA negative control. The cells were collected 24 hours later and
lysed with RIPA buffer. Fli-1 was detected by an immunoblot. The Fli-1 protein
was indicated at 51kDa in MS1 endothelial cells. Beta actin (42kDa) was used as
a control housekeeping gene and ensures equal loading of protein sample.
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Figure 3. Expression of Fli-1 was inhibited in human umbilical vein
endothelial cells with transfected specific Fli-1 siRNA
Human umbilical vein endothelial (HUVEC) cells were treated with 5nmol stealth
silencer human Fli-1 siRNA or siRNA negative control. The cells were collected
24 hours later and lysed with RIPA buffer. Fli-1 was detected by an immunoblot.
Fli-1 protein was detected at 51kDa in HUVECs. Beta actin (42kDa) was used as
a control housekeeping gene and ensures equal loading of protein sample.
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Figure 4. CXCL10 was produced in MS1 cells following LPS stimulation in
a dose-dependent way. MS1 cells were stimulated with 0.25g/ml, 0.5g/ml,
1g/ml, 5g/ml, and 10g/ml of LPS and supernatants were collected 6 hours
and 24 hours after stimulation. CXCL10 concentrations were measured via
sandwich ELISA. Experiment was performed in triplicate and values are shown
as means SEM of N=3 experiments per group. * = P<0.05; ** = P<0.01.
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Figure 5. Inhibiting expression of Fli-1 leads to significantly decreased
production of CXCL10
Murine endothelial cells were transfected with specific Fli-1 siRNA or control
negative siRNA respectively and simulated with 1g/mL LPS. The supernatants
were collected at 6 and 24 hours following the stimulation. CXCL10
concentrations were determined by a sandwich ELISA. The experiment was
performed in triplicate and values are shown as means SD of N=2 experiments
per group. *p<0.05

*

*
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Specific Aim 2 – To determine the mechanism(s) of how Fli-1 regulates the
expression of CXCL10

Fli-1 binds to the CXCL10 promoter in endothelial cells
Next, we investigated how Fli-1 regulates the expression of CXCL10. Fli-1 is
known to bind the consensus ETS DNA binding motif GGAA/T and in previous
studies the Fli-1 transcription factor has been proven to regulate many
inflammatory cytokines and chemokines by directly binding to their promoter
regions [25] [15]. Using Genomatrix Matlnspector software, the potential Fli-1
ETS binding sites in the promoter region of CXCL10 were examined. After
thorough examination, 46 putative Fli-1 binding sites were identified as shown in
Figure 6. Fourteen primer pairs were designed to cover all 46 Fli-1 binding sites
(Table 2). ChIP Assay was performed using specific anti-Fli-1 antibody to
determine if Fli-1 binds to the promoter of CXCL10 as described the methods.
We determined PCR products from ChIP 3, ChIP 4, ChIP 7, and ChIP 8 were
significantly enriched for the Fli-1 antibody compared to normal IgG control (p
values less than 0.01) (Figure 7).
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Figure 6. Putative ETS/Fli-1 binding to sites on the mouse CXCL10
promoter.
Forty-six putative binding sites were identified on the mouse genomic DNA
promoter of CXCL10 using Genomatrix MatInspector. The number above the
dash represents the number of potential ETS binding sites within each ChIP
primer region (Table 2). TSS – stands for transcription start site of the promoter.
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Table 2. ChIP Primers
The 5’ UTR from the murine CXCL10 sequence was obtained and used to
identify the promoter region of the mouse CXCL10 genome. Primers pairs were
designed to cover the Fli-1 binding sites located along the CXCL10 promoter.
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Figure 7. Fli-1 binds to the CXCL10 promoter.
MS1 endothelial cells were cross-linked with formaldehyde, chromatin was
isolated from the cells and immunoprecipitated with specific Fli-1 or control IgG
antibodies. The genomic fragments associated with the immunoprecipitated DNA
were amplified by PCR using the primers designed in Table 2. Fold changes (Fli1 antibody/control IgG) were calculated by RT-PCR and are shown for each
primer pair. Data presented are shown as the mean ± standard deviation where a
single asterisk indicates p<0.05. Data are representative of three independent
experiments.

*
*
*

*
*
***
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40

*

*

Fli-1 drives the transcription of CXCL10

DNA transfection assays were performed to determine whether Fli-1
regulates the expression of CXCL10. Using the human CXCL10 promoter, we
amplified it using PCR and genomic DNA and cloned the promoter into the pGL3
basic reporter construct. To determine if Fli-1 drives the expression of CXCL10
we transfected increasing dosages of Fli-1 into NIH3T3 embryonic fibroblast
cells, which contain no endogenous Fli-1. Looking at the luciferase data in
Figure 8, the results demonstrate that as the dosage of Fli-1 increases so does
CXCL10 expression within the promoter.
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Figure 8. Fli-1 drives activation of CXCL10.
NIH3T3 cells were transfected with murine Fli-1 expression construct and the
human pGL4/CXCL10 reporter construct using the FuGene 6 transfection
reagent. Increasing amounts of the Fli-1 expression construct (0.025g, 0.05g,
0.1g, 0.25g, 0.5g, and 1g) were transfected into NIH3T3 cells. Values are
the mean + SEM of 3 replicate experiments (n=3). * = P < 0.05.

*

*
*
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Mutation of DNA-binding domain of Fli-1 partially impairs transcriptional
activation of the CXCL10 promoter
To determine whether Fli-1 is driving transcription of CXCL10 directly or
indirectly, we performed another DNA transfection using a Fli-1 binding mutant.
The Fli-1 binding mutant contains a mutation to prevent DNA binding to the
promoter region. This mutation consists of a single amino acid change from
tryptophan 321 to arginine (W to R) [42]. Figure 9 shows that mutating Fli-1
binding domain results in reduced activation of CXCL10 compared to normal Fli1.
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Figure 9. Fli-1 regulates CXCL10 through indirect binding of the promoter and
with the help of unknown cofactors. NIH3T3 cells were transfected with human
Fli-1 expression construct and pGL4/CXCL10 reporter construct using the
FuGene 6 transfection reagent. 1g of human Fli-1 expression construct and 1g
of human Fli-1 binding mutant were transfected into NIH3T3 cells. Values are the
mean + SEM of 3 replicate experiments (n=3). * = P < 0.05.

*
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Chapter 5 – Discussion
The innate immune system is our primary line of defense to protect the
host from infection from pathogens [22]. Mammalian cells produce inflammatory
cytokines and chemokines in response to innate immune signals and their
expression is tightly regulated [20, 22]. IFN-gamma Inducible Protein (IP-10),
also known as CXCL10, is an inflammatory chemokine belonging to the CXC
chemokine family [26]. CXCL10 is chemotactic for many inflammatory cells
including macrophages and dendritic cells [26]. Altered expression of CXCL10 is
associated with inflammatory diseases, including lupus nephritis and other
autoimmune diseases; its association with numerous autoimmune diseases is
what drives interest in determining regulatory factors for this inflammatory
cytokine [26]. The Fli-1 transcription factor, a member of the Ets gene family, is
known to regulate numerous cellular processes, the immune response being one
of interest [10]. Fli-1 has also been associated with the pathogenesis of renal
injury and SLE, which has been studied in our lab. Previous studies have shown
that Fli-1 heterozygous (Fli-1+/-) NZM2410 mice, with reduced expression of the
Fli-1 transcription factor, had a marked reduction in nephritis, necrosis, and
proteinuria compared to wild-type NZM2410 mice [19]. The Fli-1+/- NZM2410
mice, also had reduced infiltration of inflammatory cells including macrophages,
T cells, B cells, and neutrophils in kidneys and survived significantly longer
compared with wild-type NZM2410 controls [19]. Our lab has demonstrated that
Fli-1 directly regulates expression of inflammatory chemokines and cytokines
including MCP-1, RANTES, and IL-6, all of which are associated with
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inflammatory diseases [15, 16, 25]. Because Fli-1+/- NZM2410 had significantly
decreased infiltration of inflammatory cells, including dendritic cells and
macrophages, and IP-10/CXCL10 is known to attract these cells, our hypothesis
was that Fli-1 is a critical regulator in directly modulating the expression of
CXCL10. Within this study we initially looked at mouse endothelial cells. As
mentioned previously, the overexpression of Fli-1 has been implicated in SLE
development and is also found in endothelial cells [16, 19, 43]. After LPS
stimulation within these cells, we saw an increase in CXCL10 production over 24
hour time period (Figure 5). With the siRNA knockdown of Fli-1 within the same
cell type we see significant reduction of CXCL10 6 and 24 hours after LPS
stimulation. Similar results have been seen within the G-SCF study where it was
determine that Fli-1 was a direct regulator (Lennard Richard et al., unpublished
data). In comparing the current data with previous studies we can conclude from
this experiment that the partial absence of Fli-1 leads to reduced CXCL10
expression. These results are consistent with our initial observation and first aim
that Fli-1 plays a role in regulation CXCL10.
Looking into the mechanism behind the relationship of Fli-1 and CXCL10
we determined that Fli-1 binds to the promoter region of CXCL10 at several
different sites based on results from the ChIP Assay (Fig. 7). We have identified
that Fli-1 binds to 6 regions within the murine promoter identified by ChIP assay
(ChIP3 [-1830 to -1660], ChIP4 [-1677 to -1501], ChIP7 [-1200 to -1027], ChIP8
[-1027 to -858], ChIP9 [-873 to -733], and ChIP10 [-753 to -602]) (Figure 7).
Since ChIP 3 and ChIP 4, ChIP 7 and ChIP 8, and ChIP 9 and ChIP 10 sites are
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very close to each other we will need to conduct further analysis within the
CXCL10 promoter to identify which sites Fli-1 actually bind to. Some proposed
methods of determining specific sites Fli-1 may bind to would be to insert a
mutation. A mutation will hopefully hinder the binding of Fli-1 and we can narrow
down the exact location where Fli-1 is binding within the promoter region.
Upon performing the transient DNA transfection, using human Fli-1
expression construct, luciferase assay results determined Fli-1 drives CXCL10
activation starting from 0.025g of Fli-1 to 0.1g of Fli-1 (Fig. 8). These results
clearly show that Fli-1, not only plays a role in the regulation of CXCL10 but
through binding of the promoter region.. Based on our data from DNA transient
transfection of the human Fli-1 binding mutant, the mechanism Fli-1 uses to
regulate the expression of CXCL10 may be both direct and indirect ways.
Mutation of Fli-1’s DNA binding domain, shown in Figure 9, shows an 18%
reduction of transcriptional activity. This is reduction is significant when
compared to the human Fli-1 expression construct (P = 0.00213). Since the
reduction is rather low, these results suggest that Fli-1 maybe driving
transcription largely indirectly and there may be other factors assisting with the
transcription of CXCL10. These results are very similar to previously published
literature looking at Fli-1 regulation of MCP-1 [44]. Our lab provided evidence that
Fli-1 regulated MCP-1 both directly and indirectly due to fact that Fli-1 was
binding to the promoter MCP-1 and driving transcription in a dose-dependent
manner [44]; however when the DNA binding mutant was introduced
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transcriptional activity was reduced by only 27%, which led researchers to
conclude that Fli-1 regulated MCP-1 largely indirectly [44].
Although we were able to provide viable evidence of Fli-1’s role in
CXCL10 expression there are a few more areas that we would like to explore
with this project. The majority of our work was conducted in pancreatic murine
endothelial cells and or fibroblast cells for our DNA transfections; and although
these cells were sufficient enough to use for our current work, our goal is to
transition to murine and/or human kidney cells in hopes to obtain similar results
and gain a greater insight on Fli-1’s role with CXCL10. This would greatly mimic
realistic views on the mechanism that is taking place and introduce more
authentic environmental factors that may be assisting Fli-1 in transcription.
In drawing conclusions from this study, Fli-1 has been identified as a
critical regulator of IP-10/CXCL10 in endothelial cells. While Fli-1 binds to the
CXCL10 promoter, the mechanism of activation is mainly through indirect binding
and interactions with the promoter. These findings differ from our original
hypothesis of Fli-1 being a direct regulator of CXCL10; however the Fli-1
transcription factor is still a critical regulator. This can be seen through results
from our first aim, siRNA knockdown of Fli-1 results in a significant reduction in
CXCL10 protein expression, and previous studies where Fli-1 is a major
regulator of other inflammatory cytokines and chemokines [15, 16, 25, 44]. There
are a number of factors that maybe assisting Fli-1 with the transcriptional
regulation of CXCL10, these include post-translational modifications and
transcriptional co-activators. Our upcoming goals are to identify the co-factors
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and post-transcriptional modifications that may be involved through use of
proteomics, specifically the MALDI-TOF mass spectrometer and other molecular
biology techniques. Many cytokines such as IFN-α and IFN-β are known to
stimulate other cytokine production; we also plan to determine if Fli-1 regulates
expression of CXCL10 following stimulation with IFN- and IFN-. The primary
goal of this project was to establish a relationship between Fli-1 transcription
factor and CXCL10 due to the fact of there being evidence of Fli-1 being a major
chemokine regulator and CXCL10 playing a role in inflammation in autoimmune
diseases. Our studies will add more to the list of chemokines that Fli-1 regulates
and contribute to further studies of the transcription factor. Lupus nephritis is the
leading cause of death in SLE patients today and our current studies will
contribute to the molecular and immunological understanding of the disease.
CXCL10 is associated with several other inflammatory diseases and role of Fli-1
in these diseases are needed to be explored.
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